AstraZeneca's chief executive is sounding the alarm about a threat that could reshape the pharmaceutical industry: the western world risks falling behind Chinese competitors the same way automakers got blindsided by electric vehicles.
Pascal Soriot, head of the British FTSE 100 company, says the industry needs to operate at what he calls "Chinese speed" to stay ahead of innovation. The warning reflects growing anxiety in Europe and the US that dominant drugmakers could wake up one day to find themselves outmaneuvered, much as Tesla and Chinese manufacturers overtook traditional carmakers focused on combustion engines.
"We have to make sure we don't fall behind," Soriot said. "What we are learning ourselves is we have to move much faster."
AstraZeneca disclosed that it remains on track to hit ambitious 2030 targets, projecting annual sales of $80 billion, up from $59 billion last year. The company reported first-half 2026 revenues of 30.7 billion pounds, a 6 percent increase year-over-year at constant exchange rates. Soriot characterized the firm's drug pipeline as "unmatched," a position he argued puts the company on solid footing despite the recent failure of Wainua, a major heart disease candidate that didn't meet expectations in clinical trials.
The setback underscores a reality Soriot embraced matter-of-factly. "We have to accept to fail some of the time," he said. "Biology is biology."
Where Chinese drugmakers are gaining ground tells a revealing story. While western companies have invested heavily in traditional approaches, their Chinese counterparts are pouring resources into emerging technologies like antibody drug conjugates, which precisely deliver chemotherapy agents to cancer cells, and cell therapy, where live cells are introduced into the body to combat disease. These represent the pharmaceutical equivalent of the battery and electric motor breakthroughs that reshaped transportation.
"Chinese companies were focused completely on electric vehicles and batteries and those kinds of technologies," Soriot observed, drawing the parallel directly.
Soriot pushed back against another anxiety gripping the industry: the fear that artificial intelligence will eliminate jobs. He argued that AI accelerates drug development and trial design while boosting productivity, potentially fueling economic growth rather than mass layoffs. "This story about AI killing jobs is a bit of a fake story," he said, noting that AI tools have made him "faster and smarter."
The executive also addressed a contentious issue hanging over AstraZeneca's relationship with the UK government: a potential deal with the United States that could force the NHS to spend billions more on medicines. The agreement, struck under pressure from Donald Trump's tariff threats, has drawn scrutiny over estimates suggesting it could lead to nearly a quarter-million excess deaths in England.
With Andy Burnham now leading the UK government, Soriot said AstraZeneca would seek clarity on how the new administration views the arrangement. He stopped short of predicting whether the leadership change would alter the outcome. "You have to establish your priorities and then fund them," he said.
Author James Rodriguez: "Soriot's Chinese speed warning deserves weight, but the real test isn't rhetoric about moving faster, it's whether western drugmakers can actually pivot their culture and investment strategies before the gap becomes unbridgeable."
Comments